Headlines Biotech Firm Receives $7.5M Grant for Glaucoma Research The money comes from the German state of Saxony. Published 4 years ago on November 6, 2019 By INVISION Staff Share Tweet NEW YORK — Q BioMed Inc., a commercial stage biotech company, announced that its technology partner, Mannin, has received a $7.5M grant from the German state of Saxony. The objective of the grant is to fund the development of novel pharmaceuticals and biologic treatments for glaucoma. INVISION Podcast Bringing Independent ECPs Into the 21st Century With the Technology Solutions a Modern Eyecare Business Needs INVISION Podcast The Making of Bespoke Eyewear, An Acetate Kitchen and Collecting Famous People’s Heads INVISION Podcast Fierce Independence, Southern Hospitality and Little Side of Unsolved Murder? The approval of the grant means that Q BioMed and Mannin “can significantly accelerate the development of these therapeutics,” according to a press release. Denis Corin, CEO of Q BioMed, said, “We are thrilled that we will be able to speed the development of these promising therapeutics and bring new innovation to glaucoma patients as soon as possible. Our partnership with Mannin and now, the government of Saxony is important to the advancement of this unique drug platform and we look forward to supporting the build-out of the Mannin European headquarters in Leipzig.” Mannin is a research-stage biotechnology company focused on the discovery, development and commercialization of therapeutics for vascular diseases. It was founded in July 2012 and is led by President and CEO Dr. George Nikopoulos. Q BioMed and Mannin have been partners since 2015. Advertisement George Nikopoulos, president and CEO of Mannin, stated, “We are very encouraged by the confidence and enthusiasm the government of Saxony has shown in our research, and we are committed to making accelerated progress through their investment.” Mannin is leveraging two distinct modes of action to reduce the intraocular pressure that causes glaucoma, utilizing different routes of administration and dosing regimens. Mannin is currently working on the preclinical development of a small molecule pharmaceutical eye-drop as well as a novel recombinant protein injectable biologic. This approach “increases the probability of success of developing a new therapy that is optimized for the needs of glaucoma patients,” according to the release. Additionally, Mannin is exploring other therapeutic opportunities using these molecules for vascular diseases. Q BioMed and Mannin intend to announce further details regarding the research program later this year. Related Topics:glaucomaLatest News Top click to Comment(Comment) Up Next $17M Grant to Support Research Linking Eye Health, Alzheimer’s Don't Miss Researchers Developing Contact Lens to Fight Dry Eye Syndrome INVISION Staff Since launching in 2014, INVISION has won 23 international journalism awards for its publication and website. Contact INVISION's editors at firstname.lastname@example.org. SPONSORED VIDEO Crizal® Sapphire™ HR: Invisible Shield of Protection Your patients’ main concerns of anti-glare, scratch resistance, and easiness to clean are covered. Crizal Sapphire HR, the latest and most advanced product in the Crizal No-Glare range, is now widely available across lab networks and through all major managed vision care providers. Crizal Sapphire HR is available with Essilor’s advanced lens designs such as Varilux® progressive lenses and Eyezen® enhanced single vision lenses. Click here to learn more. *External laboratory tests and internal technical tests – 2020. Compared to the competitor most known lens-brands by consumers (2019 external brand tracking in 11 countries). The word ’overall’ refers to anti-reflective coatings important criteria, ranked through an external quantitative consumer study – 2019. You may like Record Halloween Spending Expected: NRF 23 Painfully Relatable Memes About Working Holiday Retail Is Eyecare Ready for the Metaverse? Promoted Headlines On the Edger Maximizing Profit With In-House Finishing Visionix Made in Italy Italian Trade Agency Turn Patients Into Loyal Eyewear Shoppers Optify Advertisement Latest Trending Videos Headlines16 hours ago Record Halloween Spending Expected: NRF Photo Gallery19 hours ago 23 Painfully Relatable Memes About Working Holiday Retail Cover Stories19 hours ago Is Eyecare Ready for the Metaverse? Press Releases3 days ago Modern Optical Canada Announces New Collaboration with ZEISS Vision Care Canada Press Releases3 days ago IbisVision Launches Breakthrough Refraction Technology for Over-the-Internet Eye Prescriptions at Las Vegas Expo Photo Gallery4 weeks ago Celebrity Eyewear Pics Featuring SJP, Russell Crowe, ‘Half’ of Oasis, and Shakira (Of Course!) Photo Gallery19 hours ago 23 Painfully Relatable Memes About Working Holiday Retail Sponsored Content7 days ago Made in Italy Sponsored Content4 weeks ago Turn Patients Into Loyal Eyewear Shoppers America's Finest4 weeks ago Trading on a Good Name Sponsored Content4 weeks ago Turn Patients Into Loyal Eyewear Shoppers Sponsored Webinars2 months ago Shop! Masterclass Webinar: Sustainability for Retail: How Retailers Create Social, Environmental and Cultural Innovations Sponsored Content2 months ago Now Available: New Varilux® XR series™ Sponsored Webinars3 months ago Human-Centric Design in a Digital World: Creating Unexpected Moments That Inspire, Educate, and Connect at Retail Sponsored Content4 months ago The Very First of Its Kind: Introducing Ray-Ban Reverse Advertisement SubscribeBULLETINS Get the most important news and business ideas for eyecare professionals every weekday from INVISION. Advertisement Advertisement Most Popular Photo Gallery19 hours ago 23 Painfully Relatable Memes About Working Holiday Retail Sponsored Content7 days ago Made in Italy True Tales4 days ago The Farting Mom Chronicles: One Optician’s Terrible Tale Best of the Best1 week ago The One Tool a NY Practice Says Is ‘Essential’ in Targeting Ads to Website Visitors America's Finest6 days ago At This Alberta Practice, the Eyewear Is Global, the Exams Are Thorough and the Staff Are Valued Sponsored Content5 days ago On the Edger Maximizing Profit With In-House Finishing Headlines1 week ago National Pharmacy Chains Targeted for Unapproved Eyecare Products Columns7 days ago You’re In Optometry School… Now What?